Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients.
ABSTRACT Sepsis, affecting millions of individuals annually with an associated high mortality rate, is among the top 10 causes of death. In addition, improvements in diagnostic tests for detecting and monitoring sepsis and infection have been limited in the last 25 years. Neutrophil CD64 expression has been proposed as an improved diagnostic test for the evaluation of infection and sepsis.
To evaluate the diagnostic performance of a quantitative flow cytometric assay for leukocyte CD64 expression in comparison with the standard tests for infection/sepsis in an ambulatory care setting.
Prospective analysis of 100 blood samples from patients from an emergency department setting in a 965-bed tertiary care suburban community hospital was performed for neutrophil CD64 expression, C-reactive protein, erythrocyte sedimentation rate, and complete blood count. The laboratory findings were compared with a clinical score for the likelihood of infection/sepsis, which was obtained by a blinded retrospective chart review.
The diagnostic performance, as gauged by the clinical score, varied with neutrophil CD64 (sensitivity 87.9%, specificity 71.2%, efficiency 76.8%) and outperformed C-reactive protein (sensitivity 88.2%, specificity 59.4%, efficiency 69.4%), absolute neutrophil count (sensitivity 60.0%, specificity 50.8%, efficiency 53.8%), myeloid left shift (sensitivity 68.2%, specificity 76.3%, efficiency 73.3%), and sedimentation rate (sensitivity 50.0%, specificity 65.5%, efficiency 61.0%).
Neutrophil CD64 expression quantitation provides improved diagnostic detection of infection/sepsis compared with the standard diagnostic tests used in current medical practice.
- SourceAvailable from: David Barnett[Show abstract] [Hide abstract]
ABSTRACT: Flow cytometry and other technologies of cell-based fluorescence assays are as a matter of good laboratory practice required to validate all assays, which when in clinical practice may pass through regulatory review processes using criteria often defined with a soluble analyte in plasma or serum samples in mind. Recently the U.S. Food and Drug Administration (FDA) has entered into a public dialogue in the U.S. regarding their regulatory interest in laboratory developed tests (LDTs) or so-called home brew assays performed in clinical laboratories. The absence of well-defined guidelines for validation of cell-based assays using fluorescence detection has thus become a subject of concern for the International Council for Standardization of Haematology (ICSH) and International Clinical Cytometry Society (ICCS). Accordingly, a group of over 40 international experts in the areas of test development, test validation, and clinical practice of a variety of assay types using flow cytometry and/or morphologic image analysis were invited to develop a set of practical guidelines useful to in vitro diagnostic (IVD) innovators, clinical laboratories, regulatory scientists, and laboratory inspectors. The focus of the group was restricted to fluorescence reporter reagents, although some common principles are shared by immunohistochemistry or immunocytochemistry techniques and noted where appropriate. The work product of this two year effort is the content of this special issue of this journal, which is published as 5 separate articles, this being Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part IV - Postanalytic considerations. © 2013 International Clinical Cytometry Society.Cytometry Part B Clinical Cytometry 09/2013; 84(5):309-14. · 2.23 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Sepsis in neonates hospitalized in the neonatal intensive care unit is a global problem and is a significant contributor to morbidity and mortality. Neutrophil surface CD64, the high-affinity Fc receptor, is quantitatively up-regulated during infection and sepsis. Our goal in this prospective study was to measure the neutrophil CD64 in blood as an adjunct to our previously validated hematologic scoring system for detecting neonatal sepsis. A prospective study enrolled newborns with documented sepsis (n = 25), clinical sepsis (n = 25), and control newborns (n = 25). C-reactive protein, neutrophil CD64, complete blood counts, and blood cultures were taken. Neutrophil CD64 was analyzed by flow cytometry. CD64 was significantly elevated in the groups with documented and clinical sepsis (P < 0.001). CD64 had a sensitivity of 96%, a specificity of 100%, a positive predictive value of 96.2%, and a negative predictive value of 100% with a cutoff value of 45.8% and 46.0% in the confirmed and the clinical sepsis groups, respectively. CD64 expression on neutrophils increases significantly in neonates with sepsis and can be considered a useful diagnostic marker for early diagnosis of neonatal infection as a single determination compared with other inflammatory markers.Journal of Investigative Medicine 01/2014; · 1.50 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Neutrophil CD64 has been shown to be a promising biomarker for bacterial infection and sepsis identification. However, the prognostic value of CD64 in predicting the likelihood of survival for patients in intensive care unit (ICU) is unclear. A total of 797 patients in the ICU of Xin-Hua Hospital, Shanghai, China were enrolled. We determined the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores from these patients and collected blood samples to measure the levels of neutrophil CD64, thyroid hormone and C-reactive protein (CRP). We assessed the association between APACHE II scores or these biomarkers and mortality of patients in the ICU. Receiver operating characteristic (ROC) curves were generated and the Area Under the Curve (AUC) for each indicator was determined. The AUC for CD64 was 0.752 ± 0.026, which was higher than that of FT3 (0.696 ± 0.028) and CRP (0.672 ± 0.026). APACHE II scores had the highest AUC (0.872 ± 0.018). The level of neutrophil CD64 expression positively associated with CRP and APACHE II, and negatively correlated with FT3. Multiple regression analysis revealed that APACHE II scores (Standard β value = 0.183, P < 0.001), CD64 (Standard β value = 0.518, P < 0.001) or log (CRP) (Standard β value = 1.203, P < 0.001) independently predicted ICU mortality. CD64 had the greatest power for predicting ICU mortality other than APACHE II scores. This result indicates that CD64 may be used as a biomarker to in combination with the use of APACHE II scores to improve the accuracy of predicting mortality outcome for patients in the ICU.International journal of clinical and experimental pathology. 01/2014; 7(11):7806-13.
In press, Archives in Pathology and Laboratory Medicine
Neutrophil CD64 is an Improved Indicator of Infection or Sepsis in
Emergency Room Patients
Bruce H. Davis*
Stephen H. Olsen^
Nancy C. Bigelow*
*Trillium Diagnostics, LLC and
Maine Medical Center Research Institute
Scarborough, Maine 04074
^Department of Clinical Pathology
William Beaumont Hospital
Royal Oak, Michigan 48073
Address correspondence to: Bruce H. Davis, M.D.
Maine Medical Center Research Institute
81 Research Drive
Scarborough, Maine 04074
Inflammation, sepsis, infection, leukocyte differential, laboratory automation, Fc
receptor, sepsis assay, sepsis test, neutrophil activation, immature granulocytes, near
patient testing, medical triage
Sepsis is a significant health problem in the United States with an estimated
750,000 new cases annually [1, 2]. Sepsis is among the ten leading causes of death and
the leading cause of mortality in the non-coronary intensive care unit with a mortality rate
of 30-50% [1-4]. It is estimated that the yearly economic burden to the U.S. alone is
nearly $17 billion . The frequency of sepsis has increased over 135% in a ten-year
interval in the most recent decade and is predicted to continue to rise due in part to the
continued increase in antibiotic resistance [1, 2, 6]. In addition to the fully developed
cases of sepsis, there are millions of patients on an annual basis in the U.S. alone that
suffer severe infection or clinical symptoms similar to sepsis that require diagnostic
evaluation. Ironically, although treatment of sepsis has evolved in the last decades with
newer therapeutic options of improved antibiotics and more novel approaches, such as
inhibitors of the inflammatory and coagulation response, little has changed to improve
diagnosis or therapeutic monitoring [1, 3, 4, 6-11]. There has been some consensus put
forth to standardize the clinical signs and symptoms of sepsis, such as the PIRO staging
system . However despite the fact that in appropriate treatment and failure to
diagnosis sepsis represent the leading causes of mortality in sepsis [13, 14], diagnostic
advances in the detection and monitoring of sepsis have not entered clinical practice.
Thus, an improved diagnostic test for infection and sepsis would have both economic
and therapeutic healthcare benefits.
Diagnostic indicators of the systemic acute inflammation response to infection or sepsis
have shown few innovations in the past few decades, despite a marked advance in the
understanding of the molecular and cell biology of the effector myeloid cells and
cytokines involved in the innate immune response. The laboratory evaluation of patients
with suspected infection or sepsis has remained a battery of tests including the complete
blood count (CBC), leukocyte differential counting for evidence of a myeloid left shift,
erythrocyte sedimentation rates (ESR), C-reactive protein (CRP), and microbiologic
cultures. Only the introduction of procalcitonin (PCT) levels, as another form of acute
phase reactant with purported greater specificity to bacterial compared to viral infection,
can be touted as a new diagnostic for the evaluation of the patient with suspected
infection [15-23], but as of this writing PCT is not cleared for in vitro diagnostic use in the
United States nor universally accepted as an improved diagnostic assay of infection [24-
26]. The CBC and leukocyte differential with associated band count or myeloid left shift
of immaturity receive unjustified clinical utilization, particularly the over reliance on the
nonspecific, insensitive band counts [27-33]. Hence a persistent need exists for
improved diagnostic indictors of infection or sepsis, as well as better therapeutic
monitors in the treatment of infection so that antibiotic therapy might be less empiric.
Our previous studies have indicated that quantitative neutrophil CD64 (high affinity Fc
receptor) expression is a worthwhile candidate for evaluation as a more sensitive and
specific laboratory indicator of sepsis or the presence of a systemic acute inflammatory
response [34-39]. Other groups have reported a similar association between elevation
in neutrophil (PMN) CD64 expression and the presence of infection [40-50]. Neutrophil
CD64 is one of many activation-related antigenic changes manifested by neutrophils
during the normal pathophysiologic acute inflammatory response. PMN expression of
CD64 is up-regulated under the influence of inflammatory related cytokines such as
interleukin 12 (IL-12), interferon gamma (IFN-γ) and granulocyte colony stimulating factor
(G-CSF) [36, 51-61]. Up-regulation of CD64 in the presence of such cytokines or in
response to infection is but one of many changes elucidated in the last few decades as
part of neutrophil activation. However, PMN CD64 expression differs from the parallel
changes of increased CD45RA  and CD11b/18 [63-68] expression, as well as loss of
expression of CD16 [66, 69-72], CD62L [64, 73] and CD66b , in that the normal
baseline PMN CD64 expression is negligible. Additionally CD64 expression is stable at
room temperature for over 30 hours, in contrast to the labile expression of CD11b and
other PMN antigens [38, 74, 75]. Thus CD64 appears uniquely ideal as a surrogate
marker of neutrophil activation or a systemic acute inflammatory response as its
expression goes from our normal reference range of less than 2,000 sites per cell and
becomes up-regulated in a graded fashion depending upon the intensity of cytokines
stimulation [36, 55, 57, 61]. Furthermore the up-regulation of PMN CD64 expression
appears to be of pathophysiologic significance, as this form of Fc receptor has been
shown to functional in eliciting all the PMN functional responses utilized in anti-bacterial
responses [36, 56, 57].
In order to better assess the potential diagnostic utility of PMN CD64, we evaluated
specimens coming from patients being assessed in the emergency department of a
large tertiary care hospital. The study was also designed to examine the correlation of
PMN CD64 expression, as measured by quantitative flow cytometry, to those laboratory
tests used in the standard of care for the evaluation of the presence of infection or
sepsis. Thus, PMN CD64 was compared to PMN absolute counts, differential cell
counts for the presence of a myeloid left shift in the blood, C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), and microbiologic culture results. Determination
of the relationship between quantitative PMN CD64 measurements and current
laboratory hematology testing methodologies is a necessary prerequisite to more
focused clinical studies into the diagnostic utility of PMN CD64 as new diagnostic
approach for inflammation. We judged the efficacy of the various laboratory tests in the
diagnosis of infection/sepsis by using a clinical scoring system placing patients in groups
with varying levels of certainty for infection/sepsis. We report that PMN CD64
expression provides superior diagnostic information, relative to the standard laboratory
Methods and Materials
Sample selection. A total of 100 blood samples were randomly selected from the
routine clinical hematology laboratory at a large tertiary care hospital (William Beaumont
Hospital, Royal Oak, Michigan) using the criteria as being collected from patients being
evaluated in the hospital emergency department. Samples were selected for subsequent
flow cytometric measurement of leukocyte CD64 and other laboratory testing, which
performed within 4 hours of the patient draw time. The study protocol was reviewed and
approved by institutional human subjects review board.
Clinical Infection/Sepsis Score. A retrospective chart review on the patients was
performed at the conclusion of the study with the reviewer (EA) blinded to the neutrophil
CD64 results during assessment of the hospital course. Patients were categorized into
4 groups based upon the medical history chart review and the degree or likelihood of a
systemic acute inflammatory response as follows: group 0, no clinical or laboratory
evidence of infection or inflammatory process; group 1, clinical or laboratory evidence of
localized infection or inflammatory process with no or low probability of a systemic
inflammatory response; group 2, clinical or laboratory evidence of infection or
inflammatory process of a extensive localized nature with an undocumented probability
of eliciting a systemic inflammatory response; group 3, unequivocal clinical or laboratory
evidence of a systemic sepsis, infection or inflammatory process based upon
identification of organisms by culture or smear visualization. Group 0 had no laboratory
or clinical signs or symptoms indicative of an infectious process, nor evidence of an
inflammatory medicated disease process. Group 1 also had no evidence of a systemic
process with blood cultures being negative and if infection or tissue injury was found, it
was localized such as a laceration, cystitis, otitis, myocardial infarct, or fractured ankle.
The group 1 was quite heterogeneous, but the clinical and laboratory findings did not
indicate any reason to conclude the presence of a systemic inflammatory process.
Group 2 had clinical findings to indicate a systemic response to infection or tissue injury,
but unlike group 3 had no laboratory evidence of infection. Group 2 included patients
such as those with suspected ruptured diverticulitis or radiological evidence of
pneumonia, cultures not reported as positive, yet a clinical decision to treat for infection
was made. Group 3 have both clinical evidence of a systemic process of infection or
sepsis and laboratory documentation of an infectious etiology; this being the most
definitive group for the presence of infection, sepsis, or severe tissue injury.
Quantitation of CD64. Leukocyte CD64 expression was measured as previously
described [34, 76]. Briefly, 50 µl of whole blood or phosphate buffered saline (PBS)
diluted whole blood to adjust the leukocyte concentration below 2.5 x 109 cells/L was
incubated for 10 minutes at room temperature with saturating amounts of FITC
conjugated anti-CD64 murine monoclonal antibody (clone 22, Medarex, Inc., Annandale,
NJ, now available from Trillium Diagnostics, LLC, Scarborough, ME) or isotype control
murine antibody followed by red blood cell lysis with an ammonium chloride based red
cell lysis solution (Trillium Lyse, Trillium Diagnostics, LLC, Scarborough, ME). Samples
were then washed once and resuspended with PBS with 0.1% bovine serum albumin
(Sigma Chemicals, St. Louis, MO) pH 7.4 to a volume of 0.5 mL. Flow cytometric
analysis was performed to collect log green fluorescence, forward and log right angle
light scatter signals on a minimum of 20,000 leukocytes using a Cytoron Absolute flow
cytometer (Ortho Diagnostics, Raritan, NJ). Interassay standardization and CD64
quantitation was performed using Quantum 24 FITC calibration beads (Flow Cytometry
Standards Corp., San Juan, PR, now available through Bangs Laboratory, Indianapolis,
IN), which were analyzed at the start and finish of each flow cytometric batch run. Data
analysis was performed using light scatter gating to define the PMN population and
CD64 intensity quantified as FITC mean equivalent soluble fluorescence (MESF) units
using QuickCalTM for Winlist (Verity Software House, Topsham, ME). The PMN CD64
expression in MESF units was corrected for any non-specific antibody binding by the
subtraction of values obtained with isotype control antibody stained and flow
cytometrically analyzed in parallel.
Laboratory Tests. Complete blood counts and leukocyte 5 part differential results were
obtained using a Coulter STKS hematology blood counter using software version 1H
(Beckman Coulter, Hialeah, FL). Instrument reagents and calibration were as
recommended by the manufacturer. Microscopic leukocyte differential counts were
performed by a single observer (NCB) on all specimens derived from two Wright’s
stained blood smears based upon a 400 cell counts as detailed by NCCLS document
H20A (NCCLS, Wayne, PA). Separation of mature neutrophil from band forms was
according to the guidelines recommended by the College of American Pathologists .
The immature myeloid fraction was calculated as the number of myeloid cells at the
metamyelocyte stage or younger (myelocyte or promyelocyte) divided by the total
number of myeloid cells (neutrophils, bands, and immature forms). C-reactive protein
was determined using an immunoturbidimetric assay for the in vitro quantitative
determination of CRP in human serum and plasma on automated clinical chemistry
analyzers (Roche Integra, Roche Diagnostics, Indianapolis, IN). Erythrocyte
sedimentation rates were determined using the Westergren method.
Statistical Analysis. Linear regression analysis was performed using EXCEL ’97
software (Microsoft, Redmond, WA). Box plots and paired and unpaired two-tail t-tests
were performed using Statview 5.0 (SAS Institute, Inc., Cary, NC). Statistically
significant differences were defined a p < 0.05.
As in previous studies clinical samples were found to have variable expression of PMN
CD64 (range 261 – 41,585 MESF units) ranging from the normally low levels of <1,500
MESF units to levels above that seen in monocytes from healthy individuals. This
variability in CD64 expression demonstrates the in vivo ability of the PMN to modulate
expression of this Fc receptor. Also as observed with previous studies, the PMN
population in demonstrated a near Gaussian unimodal distribution of CD64 expression
with flow cytometric analysis, rather than the appearance of subpopulations of PMNs
with different surface expression of the antigen. Whether the PMN CD64 expression
was negligible as in the healthy state or significantly upregulated as in individuals with
sepsis or a systemic acute inflammatory response, the circulating population of PMNs in
the blood was a single cell cluster with regard to PMN CD64 express (Figure 1). Due to
this distribution as a shift of the entire population, it would be inappropriate to quantitate
the increase in CD64 expression in simplistic terms of percent positive. The only
circumstances where myeloid cells in the blood demonstrated a skewed unimodal or
approaching a bimodal appearance were observed was associated with samples having
a relative eosinophilia or an increase in immature myeloid forms (metamyelocyte stage
or younger). Eosinophils can express lower levels of CD64 or higher fluorescence due
to autofluorescence, which may differ than the PMN expression of CD64. Immature
myeloid cell normally express higher levels of CD64 compared to PMNs, where CD64 is
down regulated or lost with normal maturation. Hence, if immature myeloid forms are
present in the blood there maybe a skewness or tail to the myeloid population distribution
of CD64 expression. However, the majority of specimens show a symmetric cluster of
expression of the three major leukocyte populations as shown in figure 3.
The relationship among PMN CD64 expression, absolute neutrophil counts, manual band
counts, ESR rate, and C-reactive protein amount the blood samples in this study was
quite variable (figures 2, 3). As shown, there is variable relationship among all the
laboratory parameters, but PMN count and PMN CD64 expression showed no
significant correlation. A better relationship between increasing ESR rate or higher C-
reactive protein levels and increased PMN CD64 expression was noted, although the
correlation was not a strong one. Although the presence of circulating immature myeloid
cells (metamyelocyte and younger) were evaluated, only six of the 100 patients had
evidence of this degree of a myeloid left shift and as such, could not be evaluated for
any relative diagnostic significance or correlation with the other laboratory parameters.
Correlation of Laboratory Parameters to Clinical Observation. Chart review of all 100
patients was performed and clinical histories with regard to the episode approximate to
the blood sampling at the time of laboratory studies were scored in a blinded fashion
with regard to the clinical status into one of 4 groups defined as follows: (0) No clinical
indication of the acute inflammation, (1) Weak clinical suspicion of a significant infection
or acute inflammatory process, (2) Moderate clinical evidence of infection and/or acute
inflammation that resulted in some treatment plan towards this process, and (3) definite
clinical indication of infection and/or severe tissue trauma, shock, or acute inflammatory
process. Each of the laboratory tests was evaluated for the ability to distinguish these
four clinical groups (figure 4). The PMN CD64 expression was found to be the most
effective for significant separation of the four groups, achieving statistically significant
separation among all four groups. The groups 2 and 3 with the most likelihood of having
systemic infection or sepsis had all but two of the PMN CD64 values elevated above the
established normal range of < 1,500 MESF values.
All of the laboratory test employed in this study, when segregated into normal or
abnormal values, showed varying diagnostic power in separating the clinical sepsis
score groups. However, the neutrophil CD64 measurement showed the best specificity
and sensitivity with regard to separating the clinical sepsis score groups. The relative
diagnostic performance of the laboratory tests, as determined by sensitivity, specificity,
efficiency, positive predictive value, negative predictive value, positive and negative
likelihood ratio was evaluated in two manners. In order to determine the relative
diagnostic utility of each parameter in the most ideal conditions, the performance was
assessed in those patients with clinical infection/sepsis scores of 0, 2, and 3 (table 1).
This was done to allow elimination of the variable clinical group with a score of 1 which
are neither disease free, nor having a documented systemic inflammatory process. The
second evaluation of diagnostic performance was done with all samples, including those
with a clinical sepsis score of 1. Even with the heterogeneous group with the score 1
included in the evaluation (table 2), the neutrophil CD64 expression still demonstrated
clear superiority with a sensitivity of 87.9%, specificity of 71.2%, efficiency of 76.8%,
and a positive likelihood ratio of 3.05. Only the CRP paralleled the sensitivity of
neutrophil CD64 expression with 88.2%, but all but the band count had much lower
specificity, efficiency, and likelihood ratios.
Neutrophil CD64 expression is regulated in a graded fashion that would seemingly
parallel the degree of inflammatory response to a significant clinical process of infection
or tissue injury. Previous studies have indicated that PMN CD64 is highly correlated with
the presence of infection [34, 35, 40-47, 49, 50]. Its upregulation is controlled in a
myeloid specific fashion influenced by the cytokines involved in the acute inflammatory
response, such as IL-12, IFN-γ, and G-CSF, which occurs in a matter of hours [36, 51-
61, 78]. Thus between the rapid upregulation of CD64 expression on the neutrophil and
the normal 6 hour half life of the blood neutrophil, determination of the PMN CD64
expression should provide an indication of the current status of a patient’s systemic
acute inflammatory response to an infection. The results of this study indicate that PMN
CD64 expression is an improved diagnostic indicator of infection/sepsis in an
ambulatory patient population encountered in a large tertiary case emergency
department when compared to C-reactive protein, ESR, band counts, and absolute
neutrophil counts. Additionally the imperfect and variable correlations of PMN CD64 to
the laboratory studies currently used for infection detection indicate that CD64
expression is not simply a surrogate for any of these existing laboratory tests for
infection or sepsis currently available in most hospital laboratories.
This study suggests that all laboratory parameters may be correlated with the presence
of acute inflammation or infection, but that they are not reporting the same information.
The clinical chart review indicates neutrophil counts and immaturity indicators, such as
band counts, correlate, albeit imperfectly and with variable sensitivity and specificity, with
the presence of clinical evidence of infection and/or acute inflammation. The CD64
measurements in this study show a better correlation with and separation by clinical
scoring for the presence of an infectious or inflammatory process, suggesting a better
sensitivity and specificity with regard to detection of clinically meaningful acute
inflammation. Our findings on band counts and neutrophil counts do not differ
significantly from that previously reported [27-29, 31-33]. The weak correlation between
PMN CD64 and band counts and absolute neutrophil counts might be simply the
difference in specificity with regard to detection of an acute inflammatory response or
reflect the differing kinetic of response of these measurement during the dynamic
inflammatory response to infection or tissue injury. Our interpretation is that the study
results indicate PMN CD64 to be a more promising and meaningful diagnostic
parameter of the acute inflammatory response found in infection and sepsis.
The lack of a single highly specific and sensitive laboratory indicator of acute
inflammation has resulted in the clinical utilization of several concurrent laboratory tests
in routine practice to rule in or rule out the presence of infection or significant acute
inflammatory response. Culture results are often viewed as confirmatory but in practice
are often not utilized in treatment decisions due to their relatively slow turn around times
of up to 72 hours or more. Some investigators have proposed varying algorithms to
improve the predictive value of the relative insensitive tests of sedimentation rate, C
reactive protein, and presence of immature leukocyte populations, but even with such
approaches, there remains a need for improved diagnostics of infection . The
relative specificity of these tests is not unexpected given the number of additional
factors that can result in changes in these laboratory parameters, independent of the
presence of infection or acute inflammation, such as concurrent drug therapy, such as
steroids and adrenergic agents or the presence of myeloproliferative disorders. Even
PMN CD64 is not universally applicable, as if a patient is receiving therapeutic
interferon-gamma or G-CSF, circulating neutrophils would have a marked elevation in
CD64 without the presence of infection. Aside from these relative uncommon
treatments, myeloid cell CD64 up-regulation would appear to be a more specific and
perhaps sensitive avenue of laboratory quantitation of infection.
Thee are other antigenic changes that occur with neutrophil activation, such as
modulations in CD11b, CD18, CD16, CD62L and CD45RA, but these changes have
several relative disadvantages compared to PMN CD64 expression as a potential
diagnostic laboratory test. These other myeloid antigenic expressions show significant
expression in normal healthy individuals, often with a moderate degree of heterogeneity
in expression which may affect the diagnostic sensitivity. Additionally some of the
antigens, such as CD11b, show lability in expression or changes dependant upon
specimen handling independent of any disease state [64, 75]. The PMN expression of
CD11b can be modulated through specimen storage, temperature fluctuations, and
centrifugation. Our studies to date have indicated that PMN CD64 expression is stable
for at least 36 hours or longer in anticoagulated blood samples stored at room
temperature, thus being quite amenable to clinical laboratory testing . However,
additional prospective studies are required to more fully comprehend the utility of PMN
CD64 expression as a diagnostic indicator of infection or sepsis.
The results of this and other studies indicate a potential for PMN CD64 as a more
sensitive and specific indicator of infection or sepsis, which would facilitate therapeutic
decisions. The current study employed a method of quantitative cytometry using
reference beads standards calibrated in FITC MESF units, which now can be traceable
to a new National Institute of Standards and Technology (NIST) reference materials for
fluorescein, so called RM 8640 and SRM 1932 [79, 80]. This approach is quite suitable
for a clinical research study, but is likely too costly and complex to be performed in a
routine clinical laboratory test. Towards this end our subsequent studies are being
performed using a modification of the assay utilized in this reported study. The
subsequent generation PMN CD64 assay now being employed, called the Leuko64
assay, uses a single microbeads standard in a whole blood lyse no wash assay that
derives a PMN CD64 index utilizing dedicated software. This Leuko64 assay format is
much simpler and amenable to a clinical laboratory setting and can be completed in less
than 30 minutes, which would meet the rapid turnaround demands of an emergency
department setting. This and other previous studies to date indicate that PMN CD64 is
worthy of more thorough clinical evaluation as an improved diagnostic indicator of
infection and sepsis.
Dr Davis is owner of Trillium Diagnostics, LLC, which produces Leuko64, currently a
research use only assay kit for the measurement of leukocyte CD64 expression. This
work was presented in part at the Clinical Cytometry Society meeting in October, 2004 in
Long Beach, CA and the 13th annual Seminar on Molecular Pathology, Wm Beaumont
Hospital, Troy, MI, October 7, 2004.
Balk R. Severe sepsis and septic shock. Critical Care Clinics, 2000; 16: 179-192.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United
States from 1979 through 2000. N Engl J Med, 2003; 348(16): 1546-1554.
Bernard G, Vincent J, Laterre P, SP L, Dhainaut J, Lopez-Rodriquez A, Steingrub J, Garber
G, Helterbrand J, Ely E, Fisher C. Efficacy and safety of recombinant human activated
protein C for severe sepsis. New England Journal of Medicine, 2001; 344: 699-709.
Sands K, Bates D, Lanken P, al. e. Epidemiology of sepsis syndrome in 8 academic
medical centers. Journal of Amereican Medical Association, 1997; 278: 234-240.
Angus D, Linde-Zwirble W, Lidicker J, Clermont G, Carcillo J, Pinsky M. Epidemiology of
severe sepsis in the United States: analysis of incidence, outcome, and associated costs
of care. Crit Care Med, 2001; 29: 1303-1310.
Opal S and Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from
Gram-negative bacterial sepsis? Critical Care Medicine, 1999; 27: 1608-1616.
Horn K. Evolving strategies in the treatment of sepsis and systemic inflammatory
response syndrome (SIRS). QJM, 1998; 91(4): 265-277.
Fisher C, Agosti J, Opal S, Lowry S, Balk R, Sadoff J, Abraham E, Schein R, Benjamin E.
Treatment of septic shock with tumor necrosis receptor:Fc fusion protein. New England
Journal of Medicine, 1996; 334: 1697-1702.
Malik A, Hui CP, Pennie RA, Kirpalani H. Beyond the complete blood cell count and C-
reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis.
Arch Pediatr Adolesc Med, 2003; 157(6): 511-516.
Riedemann NC, Guo RF, Ward PA, Neff TA, Laudes IJ, Keller KA, Sarma VJ, Markiewski
MM, Mastellos D, Strey CW, Pierson CL, Lambris JD, Zetoune FS, Kunkel RG, Dilley KA,
Paulauskis JD. Novel strategies for the treatment of sepsis. Nat Med, 2003; 9(5): 517-524.
Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. Crit Care, 2004;
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent
JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
Conference. Crit Care Med, 2003; 31(4): 1250-1256.
Hotchkiss RS and Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med,
2003; 348(2): 138-150.
Carrigan S, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis.
Clin Chem, 2004; 50(8): 1301-1314.
Boeken U, Feindt P, Petzold T, Klein M, Micek M, Seyfert U, Mohan E, Schulte H, Gams E.
Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin,
SIRS, and sepsis. Thorac Cardiovasc Surg, 1998; 46(6): 348-351.
Carlet J. Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am,
1999; 13(2): 483-494, xi.
Hedlund J and Hansson L. Procalcitonin and C-reactive protein levels in community-
acquired pneumonia: correlation with etiology and prognosis. Infection, 2000; 28(2): 68-
Somech R, Zakuth V, Assia A, Jurgenson U, Spirer Z. Procalcitonin correlates with C-
reactive protein as an acute-phase reactant in pediatric patients. Isr Med Assoc J, 2000;
Kallio R, Surcel H, Bloigu A, Syrjala H. C-reactive protein, procalcitonin and interleukin-8
in the primary diagnosis of infections in cancer patients. Eur J Cancer, 2000; 36(7): 889-
Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic
inflammatory response syndrome. Clin Chim Acta, 2005; 351(1-2): 17-29.
21. Munoz P, Simarro N, Rivera M, Alonso R, Alcala L, Bouza E. Evaluation of procalcitonin as
a marker of infection in a nonselected sample of febrile hospitalized patients. Diagn
Microbiol Infect Dis, 2004; 49(4): 237-241.
Riche FC, Cholley BP, Laisne MJ, Vicaut E, Panis YH, Lajeunie EJ, Boudiaf M, Valleur PD.
Inflammatory cytokines, C reactive protein, and procalcitonin as early predictors of
necrosis infection in acute necrotizing pancreatitis. Surgery, 2003; 133(3): 257-262.
Ballot DE, Perovic O, Galpin J, Cooper PA. Serum procalcitonin as an early marker of
neonatal sepsis. S Afr Med J, 2004; 94(10): 851-854.
Neely AN, Fowler LA, Kagan RJ, Warden GD. Procalcitonin in pediatric burn patients: an
early indicator of sepsis? J Burn Care Rehabil, 2004; 25(1): 76-80.
Szakmany T and Molnar Z. Procalcitonin levels do not predict mortality following major
abdominal surgery. Can J Anaesth, 2003; 50(10): 1082-1083.
Gattas DJ and Cook DJ. Procalcitonin as a diagnostic test for sepsis: health technology
assessment in the ICU. J Crit Care, 2003; 18(1): 52-58.
Ardron MJ, Westengard JC, Dutcher TF. Band neutrophil counts are unnecessary for the
diagnosis of infection in patients with normal leukocyte counts. Am J Clin Pathol, 1994;
Banez EI. Hematologic response to acute inflammation: The band neutrohil revisited.
Tex Med, 1990; 86: 26-28.
Bentley SA. Alternatives to the neutrophil band count. Arch Pathol Lab Med, 1988; 112:
Cornbleet P and Novak R. Lack of reproducibility of band neutrophil identification despite
the use of uniform identification criteria. Laboratory Hematology, 1995; 1(2): 89-96.
Seebach JD, Morant R, Ruegg R, Seifert B, Fehr J. The diagnostic value of the neutrophil
left shift in predicting inflammatory and infectious disease. American Journal of Clinical
Pathology, 1997; 107(5): 582-591.
Coleman C, Thompson J, Bennion R, Schmit P. White blood cell count is a poor predictor
of severity of disease in the diagnosis of appendicitis. Am Surg, 1998; 64: 983-985.
Cornbleet P. Clinical utility of the band count. Clinics in Laboratory Medicine, 2002; 22:
Davis BH, Bigelow NC, Curnutte JT, Ornvold K. Neutrophil CD64 expression: Potential
diagnostic indicator of acute inflammation and therapeutic monitor of interferon-g
therapy. Lab Hematol, 1995; 1: 3-12.
Davis B. Quantitative neutrophil CD64 expression: Promising diagnostic indicator of
infection or systemic acute inflammatory response. Clinical Immunology Newsletter,
1996; 16(9): 121-130.
Schiff D, Rae J, Martin T, Davis B, Curnutte J. Increased phagocyte CD64 expression and
improved Fc-receptor mediated phagocytosis following in vivo recombinant human
interferon-g treatment of normal human subjects. Blood, 1997; 90: 2987-2994.
Davis B and Bigelow N. Comparison of neutrophil CD64, manual myeloid immaturity
counts, and automated hematology analyzer flags as indicators of infection or sepsis. Lab
Hematol, 2005; in press.
Davis B, Wallace P, Guyre P, Pathophysiology of human Fc-gamma receptors in health
and disease., in Phagocyte Function: A Guide for Research and Clinical Evaluation,
Robinson J. and Babcock G., Editors. 1998, John Wiley & Sons: New York. p. 47-76.
Qureshi SS, Lewis SM, Gant VA, Treacher D, Davis BH, Brown KA. Increased distribution
and expression of CD64 on blood polymorphonuclear cells from patients with the
systemic inflammatory response syndrome (SIRS). Clinical & Experimental Immunology,
2001; 125(2): 258-265.
Simms HH, Frank MM, Quinn TC, Holland S, Gaither TA. Studies on phagocytosis in
patients with acute bacterial infections. J Clin Invest, 1989; 83(1): 252-260.
41. Guyre PM, Campbell AS, Kniffin WD, Fanger MW. Monocytes and polymorphonuclear
neutrophils of patients with streptococcal pharyngitis express increased numbers of type
I IgG Fc receptors. J Clin Invest, 1990; 86: 1892-1986.
Herra CM, Keane CT, Whelan A. Increased expression of Fc gamma receptors on
neutrophils and monocytes may reflect ongoing bacterial infection. Journal of Medical
Microbiology, 1996; 44(2): 135-140.
Leino L, Sorvajarvi K, Katajisto J, Laine M, Lilius E, Pelliniemi T, Rajamaki A, Silvoniemi
P, Nikoskelainen J. Febrile infection changes the expression of IgG Fc receptors and
complement receptors in human neutrophils in vivo. Clin Exp Immunol, 1997; 107: 37-43.
Ng P, Li G, Chui K, Chu W, Li K, Wong R, Chik K, Wong E, Fok T. Neutrophil CD64 Is a
Sensitive Diagnostic Marker for Early-Onset Neonatal Infection. Pediatr Res, 2004; 56(5):
Ng P, Li K, Wong R, Chui K, Wong E, Fok T. Neutrophil CD64 expression: a sensitive
diagnostic marker for late-onset nosocomial infection in very low birthweight infants.
Pediatr Res, 2002; 51(3): 296-303.
Wagner C, Deppisch R, Denefleh B, Hug F, Andrassy K, Hansch G. Expression patterns of
the lipopolysaccharide receptor CD14, and the FCgamma receptors CD16 and CD64 on
polymorphonuclear neutrophils: data from patients with severe bacterial infections and
lipopolysaccharide-exposed cells. Shock, 2003; 19(1): 5-12.
Allen E, Bakke AC, Purtzer MZ, Deodhar A. Neutrophil CD64 expression: distinguishing
acute inflammatory autoimmune disease from systemic infections. Ann Rheum Dis,
2002; 61(6): 522-525.
Bakke A, Allen E, Purtzer M, Deodhar A. Neutrophil CD64 expression distnguishing acute
inflammatory autoimmune disease from systemic infections. Clinical and Applied
Immunology Reviews, 2001; 1(5): 267-275.
Moallem H, Kalayci O, Homel P, Fikrig S, Chice S, Durkin H, Michl J. Expression of
Fc(gamma)r1 (CD64) on polymorphonuclear leucocytes during progression to acquired
immunodeficiency syndrome in perinatally human immunodeficiency virus-infected
children. Scand J Immunol, 2000; 52(2): 184-189.
Layseca-Espinosa E, Perez-Gonzalez LF, Torres-Montes A, Baranda L, de la Fuente H,
Rosenstein Y, Gonzalez-Amaro R. Expression of CD64 as a potential marker of neonatal
sepsis. Pediatr Allergy Immunol, 2002; 13(5): 319-327.
Ji X, Yao T, Qin J, Wang S, Wang H, Yao K. Interaction between M-CSF and IL-10 on
productions of IL-12 and IL-18 and expressions of CD14, CD23, and CD64 by human
monocytes. Acta Pharmacol Sin, 2004; 25(10): 1361-1365.
Cassatella MA, Flynn RM, Amezaga MA, Bazzoni F, Vicentini F, Trinchieri G. Interferon
gamma induces in human neutrophils and macrophages expression of the mRNA for the
high affinity receptor for monomeric IgG (Fc gamma R-I or CD64). Biochem Biophys Res
Commun, 1990; 170(2): 582-588.
Hoffmeyer F, Witte K, Schmidt RE. The high-affinity Fc gamma RI on PMN: regulation of
expression and signal transduction. Immunology, 1997; 92(4): 544-552.
Perussia B, Daytonh E, Lazarus R, Fanning V, Trinchieri G. Immune interferon induces the
receptor for monomeric IgG1 on human moncytic and myeloid cells. J Exp Med, 1983;
Petroni KC, Shen L, Guyre PM. Modulation of human polymorphonuclear leukocyte IgG
Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids. J
Immunol, 1988; 140(10): 3467-3472.
Akerley WL, Guyre PM, Davis BH. Neutrophil activation through high-affinity Fc gamma
receptor using a monomeric antibody with unique properties. Blood, 1991; 77: 607-615.
Michon JM, Gey A, Moutel S, Tartour E, Meresse V, Fridman W, Teillaud JL. In vivo
induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood
cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). British
Journal of Haematology, 1998; 100(3): 550-556.
58. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Neutrophils
express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of
recombinant human granulocyte colony-stimulating factor. Blood, 1991; 78(4): 885-889.
Buckle AM and Hogg N. The effect of IFN-gamma and colony-stimulating factors on the
expression of neutrophil cell membrane receptors. J Immunol, 1989; 143: 2295-2301.
Gericke GH, Ericson SG, Pan L, Mills LE, Guyre PM, Ely P. Mature polymorphonuclear
leukocytes express high-affinity receptors for IgG (Fc gamma RI) after stimulation with
granulocyte colony-stimulating factor (G-CSF). J Leukoc Biol, 1995; 57(3): 455-461.
Kerst JM, van de Winkel JGJ, Evans AH, de Haas M, Slaper-Cortenbach IC, de Wit TP, von
dem Borne AE, van der Schoot CE, van Oers RH. Granulocyte colony-stimulating factor
induces hFc gamma RI (CD64antigen)-positive neutrophils via an effect on myeloid
precursor cells. Blood, 1993; 81: 1457-1464.
Patterson WP, Caldwell CW, Yesus YW. In vivo upregulation of CD45RA in neutrophils of
acutely infected patients. Clin Immunol Immunopathol, 1993; 68(1): 35-40.
Shih HC, Su CH, Lee CH. Alternations of surface antigens on leukocytes after severe
injury: correlation with infectious complications. Intensive Care Medicine, 1998; 24(2):
Macey MG, McCarthy DA, Trivedi UR, Venn GE, Chambers DJ, Brown KA. Neutrophil
adhesion molecule expression during cardiopulmonary bypass: a comparative study of
roller and centrifugal pumps. Perfusion, 1997; 12(5): 293-301.
Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, Galbusera M,
Cerletti C, Barbui T. Neutrophil activation and hemostatic changes in healthy donors
receiving granulocyte colony-stimulating factor. Blood, 1999; 93(8): 2506-2514.
Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation
in the peripheral blood of patients with cirrhosis of the liver and SIRS. Journal of
American Medical Association, 1995; 274: 58-65.
Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC. Relationships between plasma
cytokine concentrations and leukocyte functional antigen expression in patients with
sepsis. Crit Care Med, 1994; 22(10): 1595-1602.
Muller Kobold AC, Zijlstra JG, Koene HR, de Haas M, Kallenberg CG, Cohen Tervaert JW.
Levels of soluble Fc gammaRIII correlate with disease severity in sepsis. Clinical &
Experimental Immunology, 1998; 114(2): 220-227.
Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N. Neutrophil apoptosis is
associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol, 1994; 153(3):
Hubl W, Andert S, Thum G, Ortner S, Bayer PM. Value of neutrophil CD16 expression for
detection of left shift and acute-phase response. American Journal of Clinical Pathology,
1997; 107(2): 187-196.
Kabutomori O, Iwatani Y, Fushimi R, Amino N. Decrease in the density of IgG-Fc receptor
III (CD16) on "toxic" neutrophils. Acta Haematology, 1993; 89: 163-164.
Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AE. Soluble Fc
gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest,
1990; 86(2): 416-423.
Turzanski J, Crouch SP, Andrews M, Rose M, Finch R, Burden R, Holliday M, Fletcher J.
Effects of r-metHuG-CSF on polymorphonuclear leucocyte kinetics and function in
patients on continuous ambulatory peritoneal dialysis. British Journal of Haematology,
1998; 103(2): 387-396.
Elghetany M and Davis B. Impact of preanalytical variables on granulocytic surface
antigen expression: a review. Cytometry, 2005; in press.
Elghetany MT and Lacombe F. Physiologic variations in granulocytic surface antigen
expression: impact of age, gender, pregnancy, race, and stress. J Leukoc Biol, 2004;
76. Pizza F, Davis B, Hendrickson S, Mitchell J, Pace J, Bigelow N, DiLauro P, Nagieri T.
Adaptation to eccentric exercise: effect on CD64 and CD11b/CD18 expression. J Applied
Physiology, 1996; 80: 47-55.
Cornbleet P, Thorpe G, Myrick D. Evaluation of instrument flagging of left shift using
College of American Pathologists reference identification criteria. Laboratory
Hematology, 1995; 1(2): 97-104.
Perussia B, Kobayashi M, Rossi ME, Anegon I, Trinchieri G. Immune interferon enhances
functional properties of human granulocytes: role of Fc receptors and effect of
lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating
factor. J Immunol, 1987; 138(3): 765-774.
Wang L, Gaigalas A, Abbasi F, Marti G, Vogt R, Schwartz A. Quantitating fluorescence
intensity from fluorophores: Practical use of MESF values. J Res Natl Inst Stand Technol,
2002; 107: 339-353.
NCCLS, Fluorescence Calibration and Quantitative Measurement of Fluorescence
Intensity; Proposed Guideline., ed. Marti G., Vogt R., Gaigalas A., Hixson C., Hoffman R.,
Lenkei R., Magruder L., Schwartz A., Shapiro H., and Waggoner A. Vol. I/LA24-P (ISBN 1-
56238-514-3). 2003: NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania
(> 9,000 x
87.88% 60.00% 68.18% 50.00% 88.24%
77.27% 57.14% 77.27% 66.67% 57.89%
74.36% 50.00% 75.00% 50.00% 65.22%
89.47% 66.67% 70.83% 66.67% 84.62%
81.82% 58.33% 72.73% 60.00% 72.22%
3.87 1.40 3.00 1.50 2.10
0.16 0.70 0.41 0.75 0.20
Table 1. Performance statistics of diagnostic parameters in recognizing infection/sepsis
using disease presence defined by infection/sepsis scores 2 and 3 and disease absence
defined by infection/sepsis score 0. Positive predictive value (PPV), negative
predictive value (NPV), positive likelihood ratio (LR+), and the negative likelihood ratio
(LR-) show neutrophil CD64 to have the best diagnostic performance.
Table 2. Performance statistics of diagnostic parameters in recognizing infection/sepsis
using disease presence defined by infection/sepsis scores 2 and 3 and disease absence
defined by infection/sepsis scores 0 and 1. Positive predictive value (PPV), negative
predictive value (NPV), positive likelihood ratio (LR+), and the negative likelihood ratio
(LR-) show neutrophil CD64 to have the best diagnostic performance.
(> 9,000 x
68.18% 50.00% 88.24%
76.32% 65.52% 59.38%
62.50% 37.50% 53.57%
80.56% 76.00% 90.48%
73.33% 60.98% 69.39%
2.88 1.45 2.17
0.42 0.76 0.20